Why the study?
Long-term outcome data after mitral valve transcatheter edge-to-edge repair (M-TEER) for secondary mitral regurgitation under real-world conditions were lacking.
Population
1,628 patients with significant secondary MR undergoing M-TEER from the EuroSMR registry
Comparison
M-TEER outcomes across degrees of residual MR
Design
Multicenter registry study
Follow-up
5 years
Key result
M-TEER in patients with secondary mitral regurgitation was associated with a 5-year survival of 35.0% and sustained MR reduction to grade ≤2+ in 85.5% of patients.
Authors
Loading...
Sustained MR reduction and NYHA improvement at 5 years support durability in real-world practice; leaves open survival benefit versus medical therapy in broader populations.
Cohort (n=1,628)
Yes
In a large real-world registry, M-TEER provided durable long-term MR reduction and functional improvement in patients with secondary MR, with 5-year survival strongly associated with the degree of residual MR.
Stocker et al. (2024) conducted a cohort in Secondary mitral regurgitation (n=1,628). Mitral valve transcatheter edge-to-edge repair (M-TEER) was evaluated on 5-year survival. M-TEER in patients with secondary mitral regurgitation was associated with a 5-year survival of 35.0% and sustained MR reduction to grade ≤2+ in 85.5% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: